Department of Microbiology, Pathwest Laboratory Medicine WA, QEII Medical Centre, Nedlands, Western Australia, Australia.
J Clin Microbiol. 2010 Mar;48(3):862-6. doi: 10.1128/JCM.01435-09. Epub 2010 Jan 13.
Reports of a novel influenza virus type A (H1N1), now designated by the World Health Organization as pandemic (H1N1) 2009, emerged from the United States and Mexico in April 2009. The management of the pandemic in Australia required rapid and reliable testing of large numbers of specimens for the novel influenza strain and differentiation from seasonal influenza strains. A real-time reverse transcriptase PCR (RT-PCR) assay for the detection of pandemic (H1N1) 2009 was designed and used with existing real-time RT-PCR assays for seasonal influenza viruses A and B. MS2 coliphage was added to all samples and amplified as a quality control. Three duplex RT-PCR assays, each containing two primer pairs and corresponding 5' nuclease probes, were initially evaluated on control material and stored samples and showed high sensitivity and specificity. More than 11,000 clinical samples were then tested for influenza A and B matrix gene targets and specific hemagglutinin gene targets for seasonal influenza A/H1, A/H3, and pandemic A (H1N1) 2009. Minimum sensitivities and specificities were 98.8% and 100%, respectively, for pandemic (H1N1) 2009, 81.5% and 98.9% for seasonal A/H1, and 96.3% and 99.6% for A/H3. Automated sample extraction facilitated the rapid processing of samples so that the assays allowed accurate, rapid, and cost-effective screening of large numbers of clinical samples.
新型甲型流感病毒(H1N1)的报告于 2009 年 4 月起源于美国和墨西哥,世界卫生组织现已将其命名为 2009 年流感大流行(H1N1)。澳大利亚对该大流行的管理需要对大量新型流感病毒样本进行快速、可靠的检测,并将其与季节性流感病毒株进行区分。设计了一种用于检测 2009 年大流行(H1N1)的实时逆转录聚合酶链反应(RT-PCR)检测法,并与现有的季节性流感病毒 A 和 B 的实时 RT-PCR 检测法一起使用。将 MS2 噬菌体添加到所有样本中,并作为质量控制进行扩增。最初在对照材料和储存样本上评估了三个双管 RT-PCR 检测法,每个检测法都包含两对引物和相应的 5' 核酸酶探针,其具有很高的灵敏度和特异性。然后,对超过 11000 个临床样本进行了流感 A 和 B 基质基因靶标以及季节性流感 A/H1、A/H3 和大流行 A(H1N1)2009 的特定血凝素基因靶标的检测。大流行(H1N1)2009 的最低灵敏度和特异性分别为 98.8%和 100%,季节性 A/H1 为 81.5%和 98.9%,A/H3 为 96.3%和 99.6%。自动样本提取有助于快速处理样本,使得这些检测法能够对大量临床样本进行准确、快速和具有成本效益的筛选。